Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit
First Wave BioPharma can’t seem to catch a break in its efforts to bring a new drug to market for pancreatic insufficiency problems that affect most patients with cystic f
Following the launch of LifeArc’s £100 million programme, Chronic Respiratory Infection Translational Challenge (CRI TC) – for the acceleration of the development of new clinical solutions
Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall
The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin